Department of Gastroenterology, Medical Centre Rogaska, Rogaska Slatina, Slovenia.
Helicobacter. 2012 Sep;17 Suppl 1:36-42. doi: 10.1111/j.1523-5378.2012.00981.x.
Helicobacter pylori resistance rates to antibiotics vary in different countries and even in different regions of the same country. Choice of treatment is strongly dependent on antibiotic resistance rates. In some countries, triple therapy with a proton-pump inhibitor, amoxicillin, and clarithromycin is still the best option, but eradication results fall short of what would be desired (90-95%) in countries with clarithromycin resistance >20%, bismuth-containing quadruple therapy, or nonbismuth sequential or concomitant therapies may then be the preferred option. Newer antibiotic regimens are awaited. Vaccination would be the best option, especially for developing countries, but little progress has been made in designing a vaccine.
幽门螺杆菌对抗生素的耐药率在不同国家甚至同一国家的不同地区有所差异。治疗方案的选择强烈依赖于抗生素耐药率。在一些国家，质子泵抑制剂、阿莫西林和克拉霉素三联疗法仍然是最佳选择，但在克拉霉素耐药率>20%、含铋四联疗法、非铋序贯或同时疗法的国家，根除效果达不到预期（90-95%）。新的抗生素方案正在等待中。疫苗接种将是最佳选择，特别是对于发展中国家，但在设计疫苗方面进展甚微。
